Promising perspectives for the application of SDS Optic’s inPROBE technology platform for protein expression determination
25 Abril 2024 - 9:00AM
An inherent feature of oncology is personalization, i.e.,
conversion from the fit-to-all strategy based on applying the same
chemotherapy regimens to all patients with a specific type of
cancer to therapy individually tailored to the patient.
Traditional methods such as immunohistochemistry and
fluorescence in situ hybridization depend on subjective assessment
of tissue samples, sometimes leading to imprecise results. This can
result in either under-treatment or over-treatment, highlighting
the need for better diagnostics.
Recently, the concept of HER2-low expression has been proposed,
indicating low expression of the HER2, undetectable by standard
methods, but still being a positive predictive factor, and
therefore justifying the use of targeted therapy.
Fig. 1 Current paradigm of HER2 expression scoring [1]
SDS Optic’s inPROBE® marks a pivotal shift in oncology towards
personalized medicine, particularly in the assessment of protein
expression like HER2. This novel in vivo approach allows the
examination with optic fiber probe directly in the patient’s body
without tissue extraction. The interaction between the protein and
the biosensor generates an optical signal, converted into a
numerical value representing the expression level, thereby
providing objective and real-time results.
A clinical trial SDS-HER-01-2018 was conducted to evaluate the
safety and efficacy of inPROBE®. The study involved 22 breast
cancer patients, with 18 completing the trial. The aim was to
correlate HER2 concentrations detected by inPROBE® with those
determined based on conventional methods. Results indicated a
consistent trend toward correlation of higher HER2 values with
HER2-positive status defined by IHC and FISH, highlighting
inPROBE®'s potential accuracy and reliability.
The trial emphasized the safety of inPROBE®, reporting no
significant device-related complications. These outcomes have paved
the way for further research across different cancers and other
diseases where protein markers are critical.
inPROBE® not only enhances the accuracy of cancer diagnostics
and treatment but also holds potential for broader scientific and
industrial applications. Further studies and adaptations of this
platform aim to refine the measurement and expand its use to a
variety of biological materials and indications.
1. Zhang H, Peng Y. Current Biological, Pathological and
Clinical Landscape of HER2-Low Breast Cancer. Cancers 2023, 15,
126.
Media contact
Karol Maryniowski Marketing, Communication and IR Manager Mail:
press@sdsoptic.pl Tel: +48 668 346 186
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/55ad17a9-cdc2-42f2-b10e-df9c5e94362e
ProShares UltraShort S&P... (AMEX:SDS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
ProShares UltraShort S&P... (AMEX:SDS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024